Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.
Identifieur interne : 006132 ( Main/Merge ); précédent : 006131; suivant : 006133Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.
Auteurs : Susan H. Fox [Royaume-Uni] ; Mark Kellett ; A Peter Moore ; Alan R. Crossman ; Jonathan M. BrotchieSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- Adult, Aged, Anti-Anxiety Agents (pharmacology), Anti-Anxiety Agents (therapeutic use), Cross-Over Studies, Double-Blind Method, Dronabinol (analogs & derivatives), Dronabinol (pharmacology), Dronabinol (therapeutic use), Dystonia (physiopathology), Dystonia (therapy), Female, Globus Pallidus (drug effects), Globus Pallidus (physiopathology), Humans, Male, Middle Aged, Receptors, Cannabinoid, Receptors, Drug (drug effects).
- MESH :
- chemical , analogs & derivatives : Dronabinol.
- chemical , drug effects : Receptors, Drug.
- chemical , pharmacology : Anti-Anxiety Agents, Dronabinol.
- chemical , therapeutic use : Anti-Anxiety Agents, Dronabinol.
- drug effects : Globus Pallidus.
- physiopathology : Dystonia, Globus Pallidus.
- therapy : Dystonia.
- Adult, Aged, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Receptors, Cannabinoid.
Abstract
Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia-in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double-blind, randomised, placebo-controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone.
PubMed: 11835452
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003B86
- to stream PubMed, to step Curation: 003B86
- to stream PubMed, to step Checkpoint: 003958
- to stream Ncbi, to step Merge: 000665
- to stream Ncbi, to step Curation: 000665
- to stream Ncbi, to step Checkpoint: 000665
Links to Exploration step
pubmed:11835452Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><nlm:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom. shfox@hotmail.com</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name></author><author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A Peter" last="Moore">A Peter Moore</name></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R" last="Crossman">Alan R. Crossman</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M" last="Brotchie">Jonathan M. Brotchie</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:11835452</idno><idno type="pmid">11835452</idno><idno type="wicri:Area/PubMed/Corpus">003B86</idno><idno type="wicri:Area/PubMed/Curation">003B86</idno><idno type="wicri:Area/PubMed/Checkpoint">003958</idno><idno type="wicri:Area/Ncbi/Merge">000665</idno><idno type="wicri:Area/Ncbi/Curation">000665</idno><idno type="wicri:Area/Ncbi/Checkpoint">000665</idno><idno type="wicri:doubleKey">0885-3185:2002:Fox S:randomised:double:blind</idno><idno type="wicri:Area/Main/Merge">006132</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><nlm:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom. shfox@hotmail.com</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name></author><author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A Peter" last="Moore">A Peter Moore</name></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R" last="Crossman">Alan R. Crossman</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M" last="Brotchie">Jonathan M. Brotchie</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Anti-Anxiety Agents (pharmacology)</term><term>Anti-Anxiety Agents (therapeutic use)</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Dronabinol (analogs & derivatives)</term><term>Dronabinol (pharmacology)</term><term>Dronabinol (therapeutic use)</term><term>Dystonia (physiopathology)</term><term>Dystonia (therapy)</term><term>Female</term><term>Globus Pallidus (drug effects)</term><term>Globus Pallidus (physiopathology)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Receptors, Cannabinoid</term><term>Receptors, Drug (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dronabinol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Drug</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Anxiety Agents</term><term>Dronabinol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term><term>Dronabinol</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Globus Pallidus</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dystonia</term><term>Globus Pallidus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Receptors, Cannabinoid</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia-in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double-blind, randomised, placebo-controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006132 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 006132 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:11835452
|texte= Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:11835452" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |